Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
IPO Year: 2019
Exchange: NASDAQ
Website: castlebiosciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/25/2026 | $40.00 | Buy | Roth Capital |
| 12/14/2023 | $25.00 | Buy | Guggenheim |
| 1/5/2023 | $54.00 | Sector Outperform | Scotiabank |
| 1/7/2022 | $59.00 | Overweight | Stephens & Co. |
| 11/9/2021 | $85.00 → $75.00 | Outperform | SVB Leerink |
| 7/14/2021 | $80.00 → $85.00 | Outperform | SVB Leerink |
144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
8-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)
SCHEDULE 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
10-Q - CASTLE BIOSCIENCES INC (0001447362) (Filer)
8-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)
DEFA14A - CASTLE BIOSCIENCES INC (0001447362) (Filer)
DEF 14A - CASTLE BIOSCIENCES INC (0001447362) (Filer)
Fastest customizable press release news feed in the world
FRIENDSWOOD, Texas, July 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, Aug. 12, 2026, at 11:30 a.m. Eastern time.A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at https://ir.castlebiosciences.com/news-events/ir-events. A replay of the webcast will be available following the conclusion of the live broadcast.About Castle BiosciencesCastle Biosciences (NASDAQ:CSTL) is a leading diagno
Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitisFRIENDSWOOD, Texas, July 14, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the New York State Department of Health (NYSDOH) for its AdvanceAD-Tx test. AdvanceAD-Tx is a non-invasive gene expression profile test designed to guide systemic therapy selection for patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD)."We are proud to announce the final approval
FRIENDSWOOD, Texas, July 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2026, after the close of market on Thursday, July 30, 2026.Company management will host a webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.Webcast DetailsThe live webcast can be accessed here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=gbu0MZxe, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/. Please access the web
Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma Institute Australia (MIA) nomogramPatients classified as low risk by the i31-SLNB result had a 2.6% observed SLN positivity rate, falling well below the National Comprehensive Cancer Network (NCCN) 5% threshold used to consider avoiding sentinel lymph node biopsy (SLNB), compared with a 5.8% observed positivity rate for the MIA nomogramFRIENDSWOOD, Texas, June 25, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient car
Stokes was one of 22 financial leaders recognized in the Greater Houston areaFRIENDSWOOD, Texas, June 23, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that Frank Stokes, its chief financial officer, has been named a 2026 CFO Awards honoree by the Houston Business Journal. Stokes is among 22 chief financial officers from across the Greater Houston area recognized for their financial leadership and contributions to their organizations' success. Honorees will be celebrated a
FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 15, 2026, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 172 employees covering an aggregate of 204,925 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).The RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the applicable vesting commence
FRIENDSWOOD, Texas, June 16, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its TissueCypher® Barrett's Esophagus Test has surpassed 100,000 clinical test orders. TissueCypher is an AI-derived precision medicine test designed to predict a patient's five-year risk of progression from Barrett's esophagus (BE) to high-grade dysplasia or esophageal adenocarcinoma."Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), a gastrointestinal cancer associated with poor survival outcomes," said Emmanuel Gorospe, M.D., MPH, FACG, FASGE, board-certified gastr
FRIENDSWOOD, Texas, May 13, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 1:20 p.m. Eastern time. A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website or at this link. A replay of the webcast will be available following the conclusion of the live broadcast.About Cas
This marks the fifth MedTech Breakthrough Award that Castle has earned for its innovative testing solutionsFRIENDSWOOD, Texas, May 12, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its AdvanceAD-Tx test has been selected as the winner of the "Genomics Innovation Award" in the 10th annual MedTech Breakthrough Awards program, which recognizes companies driving meaningful progress and improving patient care across the global health and medical technology industry. AdvanceAD-Tx is Castle's clinically validated gene expression profile (GEP) test designed to guide systemic treatment dec
Longstanding collaborations with AIM at Melanoma, the Melanoma Research Foundation, The Skin Cancer Foundation, IMPACT Melanoma and The Sun Bus continue to advance awareness and education throughout MayFRIENDSWOOD, Texas, May 5, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its participation in a series of initiatives throughout May to celebrate Skin Cancer Awareness Month, including advocacy walks, community skin cancer screenings and patient education programs nationwide. These efforts are part of the Company's longstanding collaborations with multiple patient-focused organizations
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
Roth Capital initiated coverage of Castle Biosciences with a rating of Buy and set a new price target of $40.00
Guggenheim initiated coverage of Castle Biosciences with a rating of Buy and set a new price target of $25.00
Scotiabank initiated coverage of Castle Biosciences with a rating of Sector Outperform and set a new price target of $54.00
Stephens & Co. initiated coverage of Castle Biosciences with a rating of Overweight and set a new price target of $59.00
SVB Leerink reiterated coverage of Castle Biosciences with a rating of Outperform and set a new price target of $75.00 from $85.00 previously
SVB Leerink reiterated coverage of Castle Biosciences with a rating of Outperform and set a new price target of $85.00 from $80.00 previously
Lake Street initiated coverage of Castle Biosciences with a rating of Buy and set a new price target of $94.00
Robert W. Baird reiterated coverage of Castle Biosciences with a rating of Outperform and set a new price target of $82.00 from $87.00 previously
KeyBanc reiterated coverage of Castle Biosciences with a rating of Overweight and set a new price target of $90.00 from $70.00 previously
Canaccord Genuity reiterated coverage of Castle Biosciences with a rating of Buy and set a new price target of $84.00 from $80.00 previously
Live Leadership Updates
FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company's new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and other invited guests to commemorate the completion of the purpose-built facility. Local, state and national elected officials are expected to join the event, underscoring the significance of Castle's i
The Company is proud to collaborate on a number of additional initiatives during the month of May Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month. The first such event is a ribbon cutting to honor the City of Friendswood's designation as a Sun Safe Leadership Model City — the first in Texas — by IMPACT Melanoma. The ribbon cutting will take place at Stevenson Park in Friendswood, Texas, on Friday, May 3, 2024, at 10:00 a.m. Central time. "Skin cancer is the most common cancer in the Unit
-Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in
SAN DIEGO, May 26, 2021 /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ:CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Biosciences has gained Medicare reimbursement coverage and has had a successful
Live finance-specific insights
FRIENDSWOOD, Texas, July 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2026, after the close of market on Thursday, July 30, 2026.Company management will host a webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.Webcast DetailsThe live webcast can be accessed here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=gbu0MZxe, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/. Please access the web
FRIENDSWOOD, Texas, April 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the close of market on Wednesday, May 6, 2026. Company management will host a webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.Webcast DetailsThe live webcast can be accessed here: https://events.q4inc.com/attendee/621816679, or via the webcast link on the Investor Relation
2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025."We closed out an outstanding year with a strong fourth quarter, reflecting the strength of our innovative test portfolio, disciplined execution and the dedication of the entire Castle team who continue to d
FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/483643109, or via the webcast link on the Investor Relations page of the Company's website: htt
Delivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Q3 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q3 2024 Raising full-year 2025 revenue guidance to $327-335 million from $310-320 million Announced launch of AdvanceAD-Tx™, the Company's test designed to guide systemic treatment decision making in patients ages 12 and older with moderate-to-severe atopic dermatitis (AD) Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that
FRIENDSWOOD, Texas, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2025, after the close of market on Monday, Nov. 3, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/153584002, or via the webcast link on the Investor Relations page of the Company's website:
Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2025."Following a strong first quarter, our team closed out a very successful second quarter that we believe continued to reflect th
FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/164444215, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast
Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2025. "We are pleased with the exceptional start to the year, marked by continued growth in test report volum
FRIENDSWOOD, Texas, April 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of market on Monday, May 5, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/787806709, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast
This live feed shows all institutional transactions in real time.
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SC 13G - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SC 13G - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SC 13G - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)